SCHEMBL6695151

SCHEMBL6695151

CC(C)[Si](Oc1ccc(C(=O)C(Br)c2ccncc2)cc1)(C(C)C)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 3/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 4/20 0.36
MAPK1 P28482 2/20 0.36
TP53 P04637 1/20 0.36
HSD17B10 Q99714 1/20 0.35
CYP3A4 P08684 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
ROCK2 O75116 2/20 0.33
ROCK1 Q13464 2/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2099208 0.87 CES2 (0.42) ALDH1A1CYP1A2KMT2ANPSR1LMNA
SCHEMBL2936991 0.86 CA12 (0.37) ALDH1A1CYP1A2KMT2ALMNAHSD17B10
SCHEMBL6779593 0.86 ALDH1A1 (0.49) ALDH1A1CYP1A2KMT2ANPSR1LMNA
SCHEMBL6781754 0.85 ALDH1A1 (0.37) ALDH1A1CYP1A2KMT2ANPSR1LMNA
SCHEMBL6700604 0.84 MAPT (0.41) ALDH1A1KMT2AMAPT
SCHEMBL7140563 0.82 CYP1A2 (0.54) ALDH1A1CYP1A2KMT2ANPSR1LMNA
Bromide SCHEMBL6284177 0.81 CYP1A2 (0.53) ALDH1A1CYP1A2KMT2ANPSR1LMNA
SCHEMBL2099038 0.81 ALDH1A1 (0.42) ALDH1A1CYP1A2KMT2ALMNAMAPK1
SCHEMBL7141616 0.79 RAB9A (0.42) ALDH1A1CYP1A2KMT2ALMNATP53
SCHEMBL2935375 0.79 LMNA (0.36) ALDH1A1CYP1A2KMT2ALMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044226-A1 Estrogen receptor modulators DININNO FRANK P (US) 2004-03-04 US disclosed
EP-1333827-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2003-08-13 EP disclosed
EP-1328522-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2003-07-23 EP disclosed
WO-2002032377-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-04-25 WO disclosed
WO-2002032373-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044226-A1 Estrogen receptor modulators GPER1, ESR2, ESRRA ALDH1A1 1455/4885CYP1A2 731/4885KMT2A 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.